CONCENTRATIONS	9 Months Ended
Sep. 30, 2023
CONCENTRATIONS
CONCENTRATIONS	(15) CONCENTRATIONS For the three months ended September 30, 2023, the Company sourced approximately 57% of the supplies for its electrotherapy products from four significant vendors. For the same period in 2022, the Company sourced approximately 39% of the supplies for its electrotherapy products from two significant vendors. For the nine months ended September 30, 2023, the Company sourced approximately 47% of supplies for its electrotherapy products from four significant vendors. For the same period in 2022, the Company sourced approximately 33% of supplies for its electrotherapy products from two significant vendors. At September 30, 2023, the Company had no receivables from any third-party payers that made up over 10% of the net accounts receivable balance. At December 31, 2022, the Company had receivables from one third-party payer which made up approximately 14% of the net accounts receivable balance.

CONCENTRATIONS

9 Months Ended

Sep. 30, 2023

(15) CONCENTRATIONS

For the three months ended September 30, 2023, the Company sourced approximately 57% of the supplies for its electrotherapy products from four significant vendors. For the same period in 2022, the Company sourced approximately 39% of the supplies for its electrotherapy products from two significant vendors.

For the nine months ended September 30, 2023, the Company sourced approximately 47% of supplies for its electrotherapy products from four significant vendors. For the same period in 2022, the Company sourced approximately 33% of supplies for its electrotherapy products from two significant vendors.

At September 30, 2023, the Company had no receivables from any third-party payers that made up over 10% of the net accounts receivable balance. At December 31, 2022, the Company had receivables from one third-party payer which made up approximately 14% of the net accounts receivable balance.